BioanalysisVol. 6, No. 16 CommentaryChanging face of the healthcare industry: what is the possible future impact on bioanalysts?Howard M HillHoward M HillResolvPharma Consultancy Ltd, Harrogate, North Yorkshire, UK; E-mail Address: howardmhill@btinternet.comSearch for more papers by this authorPublished Online:21 Oct 2014https://doi.org/10.4155/bio.14.131AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: bioanalysisbiomarkersinnovationinstrumentationmillenialsQALYtrainingworkforceReferences1 Health expenditure, total (% of GDP). www.data.worldbank.org/indicator/SH.XPD.TOTL.ZS.Google Scholar2 NHS England. NHS allocations for 2013/2014. www.england.nhs.uk/allocations-2013-14.Google Scholar3 Mayo Clinic. Metabolic syndrome. www.mayoclinic.org/diseases-conditions/metabolic - syndrome/basics/definition/con-20027243.Google Scholar4 NHS Choices. Metabolic syndrome. www.nhs.uk/conditions/metabolic-syndrome/Pages/Introduction.aspx.Google Scholar5 NIH National Heart, Lung and Blood Institute. What is metabolic syndrome? www.nhlbi.nih.gov/health/health-topics/topics/ms.Google Scholar6 WHO. About diabetes. www.who.int/diabetes/action_online/basics/en.Google Scholar7 2013 Alzheimer's disease facts and figures. www.alz.org/documents_custom/ff_infographic_2013.pdf.Google Scholar8 Global Cancer Facts and Figures (2nd Edition). www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf.Google Scholar9 UK National Statisitcs. UK National Statistics Publication Hub, Topic Guide to: pharmacy services. www.statistics.gov.uk/hub/health-social-care/specialist-health-services/pharmacy-services/index.html.Google Scholar10 Methods for the estimation of the NICE cost–effectiveness threshold. Centre for Health Economics, University of York, UK (2013). www.york.ac.uk/media/che/documents/reports/resubmitted_report.pdf.Google Scholar11 Woodcock J, Woosley R. The FDA critical path initiative and it's influence on new drug development. Annu. Rev. Med. 59, 1–12 (2008).Crossref, Medline, CAS, Google Scholar12 US FDA. Access list of companion diagnostics devices. In vitro imaging tools. www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm301431.htm.Google Scholar13 US Department of Health and Human Services, US FDA, CDER, CBER. Guidance for Industry Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products. Center for Drug Evaluation and Research, Rockville, MD, USA (1998).Google Scholar14 Draft Guidance for Industry, Clinical Laboratories and FDA staff. In vitro diagnostics multivariant index assay – July 26, 2007. US Department of Health and Radiological Health Office In Vitro Diagnostic Device Evaluation and Safety.Google Scholar15 Laifenfeld P, Drubin DA. Early patient stratification and predictive biomarkers in drug discovery and development; a case study if ulcerative colitis and anti-TNF therapy. Adv. Exp. Med. Biol. 736, 645–653 (2012).Crossref, Medline, CAS, Google Scholar16 Piran S, Liu P, Morales A, Herschberger RE. Where genome meets phenome; rationale for integrating genetic and protein biomarkers in the diagnosis and management dilated cardiomyopathy and heart failure. J. Am. Coll. Cardiol. 60(4), 283–289 (2012).Crossref, Medline, CAS, Google Scholar17 GlaxoSmithKline. GSK McLaren Groups Joined forces in Sept 2012 to create a long term strategy collaboration to bring together the best approaches to innovation. www.gsk.com/about-us/corporate-partnerships/mclaren-partnership.html.Google Scholar18 The Christie goes on the road as it launches its mobile chemotherapy units. www.christie.nhs.uk/about-the-christie/latest-news/2013/111013.aspx.Google Scholar19 Outsourcing Pharma.com. ‘Arrogance’ and animal testing, the hurdles to outsourcing. www.outsourcing-pharma.com/Preclinical-Research/Arrogance-and-animal-testing-the-hurdles-to-outsourcing.Google Scholar20 Howe N, Strauss W. Millennials Rising: The Next Great Generation. Vintage, NY, USA (2000).Google Scholar21 Goldkorn A, Ely B, Quinn D et al. Circulating tumour cell counts are prognostic of overall survival in SWOGS0421: a Phase III trial of docetaxel with or without atrasentan for metastatic castration – resistant prostate cancer. J. Clin. Oncol. 32(11), 1136–1142 (2014).Crossref, Medline, CAS, Google Scholar22 Global Talent Statergy. 2012 global talent shortages by sector (PWC study). http://globaltalentstrategy.com/en/article/2012-global-talent-shortages-by-sector-pwc-study-299.Google Scholar23 Twenty Recruitment Group. Skills shortages continue to trouble pharmaceutical sector. www.twentyrecruitment.com/blog/?p=1060.Google Scholar24 Cambridge Network. Skills shortage prompts response by University of Hertfordshire and Melbourn Scientific. www.cambridgenetwork.co.uk/news/skills-shortage-prompts-univ-of-herts-and-melbourn-scientific/?.Google ScholarFiguresReferencesRelatedDetails Vol. 6, No. 16 Follow us on social media for the latest updates Metrics Downloaded 118 times History Published online 21 October 2014 Published in print August 2014 Information© Future Science LtdKeywordsbioanalysisbiomarkersinnovationinstrumentationmillenialsQALYtrainingworkforceFinancial & competing interests disclosureThe author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download
Read full abstract